LORIS: A Simplified Tool to Predict Immune Checkpoint Therapy Outcomes

The LORIS (Logistic Regression-Based Immunotherapy-Response Score) clinical tool offers a robust and interpretable method for predicting outcomes with immune checkpoint blockade (ICB) therapy. By analyzing data from 2,881 ICB-treated and 841 non-ICB-treated patients across 18 cancer types, researchers developed a six-feature logistic regression model that outperforms existing biomarkers. LORIS accurately predicts treatment responses, even in patients with low tumor mutational burden or PD-L1 expression, and correlates strongly with both short- and long-term survival. Its near-monotonic relationship with ICB response probability allows precise patient stratification, enhancing clinical decision-making. Accessible as an online tool, LORIS provides a practical, data-driven approach to optimize ICB therapy and maximize patient outcomes.